AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02212288 — intervention group
Intervention type: OTHER
Intervention: Urine sample
Description: Urine sample for biological investigation
Study NCT00281671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nesiritide
Description: nesiritide 0.015 mcg/kg/hour x 10 hours
Study NCT00281671 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride infusion
Study NCT02203422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporin A
Description: given orally at a dose of 1.5-2.0mg/kg twice daily for 3 consecutive months, adjusted to maintain serum levels between 200-400 ng/ml and tapered by 50 mg/d per week if patients achieved a complete response.
Study NCT02203422 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporin A
Description: given orally at a dose of 1.5-2.0mg/kg twice daily for 3 consecutive months, adjusted to maintain serum levels between 200-400 ng/ml and tapered by 50 mg/d per week if patients achieved a complete response.
Study NCT02203422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhTPO
Description: given subcutaneously at a dose of 300 Units/kg for 14 consecutive days, following with a flexible dosage depending on platelet count until the 29th day
Study NCT00593489 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Basal Insulin Initiation Strategy
Description: This multifaceted intervention consists of (1) Diabetes Specialist Consultation Support which entails specialists and educators providing consultation for insulin initiation and titration for the 12 months following the Workshop. Support will consist of prearranged and scheduled communications to review and advise for the first 2 months and will continue on an ad hoc basis for the remaining 10 months, with communication initiated by the physician (2)Community Pharmacy Insulin Initiation consists of trained community pharmacists providing patient education insulin initiation. Education will consist of one individual teaching session, one hour in duration, to review the insulin prescription protocol, insulin injection method, management of hypoglycemia, and self-monitoring of blood glucose.
Study NCT02131597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guadecitabine
Description: Given SC
Study NCT02646930 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial biopsy
Description: Endometrial biopsy in women undergoing first IVF cycle
Study NCT03591393 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: questionnaire
Description: Validated self-administered questionnaires with five domains: Wexner questionnaire for anal incontinence, PAC-SYM for constipation, International Consultation on Incontinence Questionnaire Short Form for urinary incontinence, the Pelvic Organ Prolapse Distress Inventory for pelvic organ prolapse, POP/UI Sexual Questionnaire - IUGA revised for sexual function.~The body image perception will be assessed using the Dutch-validated version of the self-administered Body Image Disturbance Questionnaire.
Study NCT01413516 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking cessation counseling
Description: Counseling sessions provided by a trained smoking counselor
Study NCT01413516 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Smoking cessation counseling
Description: Counseling sessions provided by a trained smoking counselor
Study NCT01413516 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill without any active medication
Study NCT01413516 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Varenicline (an approved medication for smoking cessation)
Study NCT03452332 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV
Study NCT03452332 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03452332 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Undergo SABR
Study NCT03452332 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Given IV
Study NCT03762486 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: 4 electrodes were placed 2-3 cm lateral to the incision of the patients at the 30th minute and 2, 18, 22, 42, and 46th hours after the surgery and electrical stimulation was implemented at varying frequencies of 2-100 Hz for 30 minutes, at a maximum current intensity of 12 milliamperes that would not bother the patient or create muscle contractions, with a pulse duration of 0.25 min
Study NCT03762486 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TAES
Description: 4 electrodes were placed at the ST25, P6, ST36, and LI4 acupuncture points of the patients at the 30th minute and 2, 18, 22, 42, and 46th hours after the surgery and electrical stimulation was implemented at varying frequencies of 2-100 Hz for 30 minutes, at a maximum current intensity of 12 milliamperes that would not bother the patient or create muscle contractions, with a pulse duration of 0.25 min
Study NCT00003521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Patients with Soft Tissue Sarcoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study NCT06180265 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: presepsin, procalciton, endotoxin
Description: measurement of presepsin, procalciton, endotoxin plasmatic levels
Study NCT03562741 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Transplantation of Screened donor stool as part of Fecal Microbiota Transplantation
Study NCT00324480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvocidib
Description: Given IV
Study NCT00324480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally
Study NCT00324480 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01922882 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Amagugu Counseling Intervention
Description: 6-session home-based counseling intervention delivered by lay counselors at mothers' homes
Study NCT00003935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Study NCT00003935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Study NCT00003935 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT05522283 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Stool and blood CMV PCR
Description: Quantitative stool CMV-PCR (CMV R-gene® kit, limit of detection 450 copies/ml, Biomerieux, France) and quantitative serum CMV-PCR (Cobas® CMV, limit of detection 150 copies/ml, Roche, USA) were collected within seven days of colonoscopy.
Study NCT01656707 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACRA
Description: Ten weekly,60-minute therapy sessions including six individual, two parent/guardian and two joint (individual and parent/guardian).
Study NCT01656707 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT
Description: 10 weekly, 60-minute sessions of augmented individualized CBT
Study NCT01618240 — intervention group
Intervention type: OTHER
Intervention: Muscle Strength Measurement
Description: MRC score (0-60) is a clinical assessment of muscle power on abduction of the arm, flexion of the forearm, extension of the wrist, flexion of the leg, extension of the knee and dorsal flexion of the foot with the score of (0-5) on each measurement
Study NCT01618240 — intervention group
Intervention type: OTHER
Intervention: Ventilator
Description: A mechanical ventilator is used to assist or replace spontaneous breathing.
Study NCT04035343 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Face down positioning
Description: See description of the face down positioning group
Study NCT04035343 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supine positioning
Description: See description of the supine positioning group
Study NCT02811120 — intervention group
Intervention type: OTHER
Intervention: venepuncture only
Description: single venepuncture
Study NCT02054039 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Incentive spirometry (IS)
Description: Mechanical devices activated by an inspiratory effort, which is viewed by the elevation of a plateau or balls in a transparent cylinder having a calibrated scale that displays the inspired flow.
Study NCT02054039 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Breath Stacking (BS)
Description: Equipment with a one-way valve that masks and promotes the accumulation of successive inspiratory volumes, preventing expiration
Study NCT00069836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone/metformin
Study NCT01860911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Study NCT01860911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NG-monomethyl-L-arginine
Study NCT03247517 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was administered once daily
Study NCT03108703 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: 35-40 Gy delivered in 5 fractions
Study NCT02835703 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical repair of coarctation of aorta
Description: Surgical repair of coarctation of aorta with aortic arch hypoplasia under CPB
Study NCT01238913 — intervention group
Intervention type: PROCEDURE
Intervention: Endoscopy
Description: Endoscopic placement of an esophageal metal stent as per medical indication.
Study NCT04343573 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Involved-field Photon Radiation Therapy
Description: Involved field photon RT including WBRT and/or focal spine RT (30Gy in 10 fractions)
Study NCT04343573 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Craniospinal Irradiation (CSI)
Description: Proton CSI (30Gy \[RBE\] in 10 fractions)
Study NCT04343573 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Proton Craniospinal Irradiation (CSI)
Description: Proton CSI (30Gy \[RBE\] in 10 fractions)
Study NCT04343573 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurocognitive Assessment
Description: All patients at MSKCC will complete a neurocognitive test battery at study entry (prior to RT), and approximately 3, 6 and 12 months and post -RT. The neurocognitive tests consists of standardized, validated and reliable measures of attention, executive functions, and memory, for which age- and education-matched healthy control published data are available. Patients will also complete self-report mood and fatigue scales at each of the same time points. This testing will only be done at MSKCC. Non-English-speaking patients and pediatric patients are exempt from completing the neurocognitive assessments. Neurocognitive assessments will be performed in person at MSK-Manhattan; an option to perform follow up assessments via telehealth will be available only for patients who are not able to go to Manhattan for these visits.
Study NCT04343573 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Neurocognitive Assessment
Description: All patients at MSKCC will complete a neurocognitive test battery at study entry (prior to RT), and approximately 3, 6 and 12 months and post -RT. The neurocognitive tests consists of standardized, validated and reliable measures of attention, executive functions, and memory, for which age- and education-matched healthy control published data are available. Patients will also complete self-report mood and fatigue scales at each of the same time points. This testing will only be done at MSKCC. Non-English-speaking patients and pediatric patients are exempt from completing the neurocognitive assessments. Neurocognitive assessments will be performed in person at MSK-Manhattan; an option to perform follow up assessments via telehealth will be available only for patients who are not able to go to Manhattan for these visits.
Study NCT04343573 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MDASI-BT and MDASI-SP
Description: Using MDASI-BT and MDASI-SP questionnaires before, weekly during, at 3 months (+/- 4 weeks), 6 months (+/- 4 weeks), 9 months (+/- 4 weeks), and 12 months (+/- 4 weeks) after group assignment, and at CNS disease progression. Only one set needs to be completed. Non-English-speaking patients and pediatric patients are exempt from completing the patient-reported outcomes unless translated PRO assessment forms are available. Questionnaires will be completed via mail, in-person, or online (MSK Engage).
Study NCT04099706 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Autologous Fat Grafting / Fat Transplant
Description: See arm descriptions.
Study NCT04099706 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Fat Grafting / Fat Transplant
Description: See arm descriptions.
Study NCT04343573 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MDASI-BT and MDASI-SP
Description: Using MDASI-BT and MDASI-SP questionnaires before, weekly during, at 3 months (+/- 4 weeks), 6 months (+/- 4 weeks), 9 months (+/- 4 weeks), and 12 months (+/- 4 weeks) after group assignment, and at CNS disease progression. Only one set needs to be completed. Non-English-speaking patients and pediatric patients are exempt from completing the patient-reported outcomes unless translated PRO assessment forms are available. Questionnaires will be completed via mail, in-person, or online (MSK Engage).
Study NCT00295789 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy: Paclitaxel/Cisplatin
Description: Drug: chemotherapy: Paclitaxel/Cisplatin
Study NCT01842646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04449913
Description: Patients will be enrolled according to a two-step study design. Twenty patients will be enrolled in the first stage. All patients will be given a daily oral dose of PF-0444913 100 mg for up to 4 cycles, with an optional continuation phase. Dose escalation to 200 mg will be provided for patients who do not have at least hematologic improvement following 2 cycles, and dose reduction to 50 mg will be permitted for patients with significant toxicity. If at least 2 patients respond in the initial stage, and additional 15 patients will be enrolled in the second stage.
Study NCT03276572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 225Ac-J591
Description: 225Ac-J591 (13.3 KBq/Kg - 93.3 KBq/Kg or 0.36 uCi/Kg - 2.52 uCi/Kg) on day 1
Study NCT03667508 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rapid Maxillary Expanding Device
Description: The expansion screw will be turned two times in the first day, and then daily until the correction is achieved.
Study NCT03667508 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Slow Maxillary Expanding Device
Description: The expansion screw will be activated every five days until correcting the crossbite.
Study NCT00295789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy: Paclitaxel/Carboplatin
Description: Drug: chemotherapy: Paclitaxel/Carboplatin
Study NCT04454060 — intervention group
Intervention type: PROCEDURE
Intervention: Extracapsular arthroscopy
Description: Extracapsular arthroscopy method was used to treat refractory tennis elbow
Study NCT02990715 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-Scan System
Description: 1. To establish the efficacy of C-Scan Capsule System and FIT in detecting patients with polypoid lesions ≥ 10mm, compared with Optical Colonoscopy~2. To evaluate the safety of the C-Scan Capsule System procedure
Study NCT02990715 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: C-Scan System
Description: 1. To establish the efficacy of C-Scan Capsule System and FIT in detecting patients with polypoid lesions ≥ 10mm, compared with Optical Colonoscopy~2. To evaluate the safety of the C-Scan Capsule System procedure
Study NCT01603225 — intervention group
Intervention type: PROCEDURE
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: Delivery of transcranial direct current stimulation for 30-60 minutes or sham stimulation.This will be administered by two or more similar devices.
Study NCT02243683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AX-024.HCl
Study NCT02243683 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT04486547 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information-Motivation-Behavioral Skills model-based intervention
Description: Home visits were made to the study group and nursing interventions were administered in accordance with the components of the Information-Motivation-Behavioral Skills model
Study NCT01904929 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walk-tests
Description: Patients will make a 6-minute-walk-test, the 400m-walk-test and a 200m-fast walk test. These first 2 tests (TM6min and TML400m) will be made in an order determined by randomization.~This series of test will be repeated 72 hours later for the study reproducibility.~It will be followed by a phase of rest of 15 min and a test of effort on travelator, according to the protocol of  modified Bruce  in moderation of portable VO2.
Study NCT00572104 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resistance exercise
Description: 12 month training intervention of weight resistance exercise. All participants receive a daily calcium and vitamin D supplement
Study NCT00572104 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: plyometric exercise
Description: 12 month training intervention of plyometric exercise. All participants receive a daily calcium and vitamin D supplement
Study NCT01896830 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clostridium difficile Toxoid Vaccine
Description: 0.5 mL, intramuscular
Study NCT01896830 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% normal saline
Description: 0.5 mL, intramuscular
Study NCT04691037 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CCTA
Description: All patients underwent CCTA according to established guidelines and local institutional protocols. The imaging data were evaluated using different image post-processing software to comprehensively analyse anatomical, functional and histological information of coronary.
Study NCT03079531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Secukinumab 300 mg administered subcutaneously.
Study NCT04232982 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transscleral cyclphophotocoagulation using the Micropulse system ( IRIDEX IQ810 Laser systems, Mountain View, CA).
Description: Treatment will be applied over the limbal area to treat the ciliary body. The treatment will be delivered with an energy of 2000mW, a cycle of 31,33% and an on/off time of 0,5ms and 1,1ms. It will be delivered around a 360° surface with avoidance of the 3 and 9 o'clock areas. The treatment will be delivered during 80 secondes in each hemisphere and will be repeated twice, for a total of 320 secondes.
Study NCT04232982 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: G-Probe transscleral cyclphophotocoagulation (Iris Medical Instruments, Montain View, CA)
Description: Treatment will be applied over the limbal area to treat the ciliary body. Sixteen (16) shots in total, which is four (4) shorts per quadrants, will be transmitted with a power from 1750 to 2000mV (titrating according to an audible pop) for a length of 2,0 secondes per shots. Treatment will be delivered around a 360° surface and avoiding the 3 and 9 o'clock areas.
Study NCT01266330 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low Dairy
Description: Less than 0.5 standard servings of dairy products per day
Study NCT01266330 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Adequate Dairy
Description: 3.5 standard servings of dairy foods per day
Study NCT02060786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: generic clopidogrel (Plavitor® )
Study NCT02060786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: original clopidogrel (Plavix® )
Study NCT04587882 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth
Description: Participants will receive weekly activity summaries and tailored notifications about their activity and goal setting behaviors.
Study NCT04587882 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants will get usual care and wear a smartwatch.
Study NCT04554732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Keratinocyte growth factor
Description: At the end of 4 cycles of chemotherapy, primary efficacy end point data will be collected. After 20 evaluable subjects if ≥ 4 responses were noted, part 2 of the study will be activated. The decision rule is based on the lower bound of a one-sided 95% confidence interval; at least 4 out of 20 patients with response results in a lower bound greater than 5% success. The proportion with success and the lower bound of a one-sided exact confidence interval will be computed.